Trelstar La 3,75 mg/ 11,25 mg/ 22,5 mg powder for prolonged-release suspension for injection
PDF Leaflet Revision Date: 25 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of locally advanced or metastatic hormone-dependent prostate cancer.
Dosage (summary)
3.75 mg monthly, 11.25 mg every 3 months, or 22.5 mg every 6 months as IM injection.
Onset of Action / Duration
Onset: 2-4 weeks, Duration: up to 6 months
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not indicated for females; potential reproductive effects noted in animal studies.
Key Drug Interactions
- QT prolonging agents
- Hormonal therapies
Contraindications
- Hypersensitivity to GnRH or its analogues
- Spinal cord compression
- Hormone independent prostate carcinoma
- Post-orchidectomy
Common side effects
- Hot flushes
- Erectile dysfunction
- Decreased libido
Counselling Points
- Monitor testosterone and PSA levels
- Inform about potential initial symptom worsening
- Advise on injection site rotation
Serious warnings
- Risk of osteoporosis
- Potential for pituitary adenoma
- Increased risk of depression
Important Disclaimer
The Trelstar La 3,75 mg/ 11,25 mg/ 22,5 mg powder for prolonged-release suspension for injection professional information leaflet below is the property of Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
